Regencell Bioscience Holdings Limited
Price Action
Technical Summary
CONSOLIDATINGRegencell Bioscience Holdings Limited is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 6), showing significant lag compared to the market leaders. Earnings growth of 57% provides fundamental context to the price action. However, RSI is deeply oversold at 17, suggesting potential for a mean-reversion bounce.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $19.61 | -43.50% | BELOW |
| 50 SMA | $24.92 | -55.53% | BELOW |
| 100 SMA | $25.89 | -57.20% | BELOW |
| 150 SMA | $24.71 | -55.15% | BELOW |
| 200 SMA | $22.43 | -50.59% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RGC in an uptrend right now?
RGC has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is RGC overbought or oversold?
RGC's RSI (14) is 17. The stock is oversold (RSI < 30), which could indicate a bounce opportunity.
Is RGC outperforming the market?
RGC has a Relative Strength (RS) Rating of 6 out of 99. RGC is currently lagging the broader market.
Where is RGC in its 52-week range?
RGC is trading at $11.08, which is 16% of its 52-week high ($69.00) and 3% above its 52-week low ($9.39).
How volatile is RGC?
RGC has a Beta of 1.23 and 52-week volatility of 147%. It's more volatile than the S&P 500 - expect bigger swings.